##  [Oxford University Hospitals NHS Foundation Trust, Level 3, John Radcliffe Hospital Headley Way, Headington OX3 9DU](/uk-en/about/partnerships/collaborative-working/oxford-university-hospitals-nhs-foundation-trust-SACT "Oxford University Hospitals NHS Foundation Trust,  Level 3, John Radcliffe Hospital Headley Way, Headington OX3 9DU") 

 **Project Name:** Oxford Oral Systemic Anti-Cancer Therapy (SACT) project manager collaborative working

**Project Summary:**

The CWP, through the development of a new role, Oral Systemic Anti-Cancer Therapy (SACT) Project Manager, aims to implement a programme of changes via a number of projects to the Trust’s oncology service. Ultimately, this will:

- Create more efficient and effective Oral SACT pathways resulting in more patients in clinics, referrals seen more quickly, faster implementation of NICE TAGs, and release of consultant time​;
- Result in a conservative estimate of 300 extra clinic slots per year that would be utilised by the project manager through streamlining workforce and expanding digital capacity;​
- Lead to a reduction in triage and clinical nurse specialist (CNS) telephone calls
- Lead to a reduction in unintended admissions.​

In order to achieve this strategy, the CWP will recruit a Band 7 Project Manager for 24 months. The total length of the CW Project will therefore be 30 months. This will accommodate 3 months at the start to recruit the Project Manager and 3 months at the end to write an outcomes report.

**Expected Benefits:**

***Anticipated Benefits for Patients:***

- Increased access to equitable and consistent and standardised care.
- Single point of contact for patients receiving oral SACT to ensure more personalised care.
- Increased access to education and information on oral SACT
- Improved adherence and consequently improve patients' outcomes, supported by a personalised care plan.
- Improved patient satisfaction and reduced waiting time (to access overbooked clinics).
- Reduced patient in-person attendance.
- Reduce unplanned medical reviews and admissions.

***Anticipated Benefits for the Organisation(s):***

- Increase the overall quality of care and improve equity of access to specialist care for patients on oral SACT requiring treatment initiation, evaluation, and monitoring.
- Improved clinician experiences.
- Maximise the capacity of each SACT clinic

***Anticipated Benefits for Novartis:***

- Better understanding of overall HCP and patient needs
- Optimal use of medicines in line with local/national guidance (including Novartis medicines) in appropriate patients.
- Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation

**Start Date & Duration:** October 2025, for 30 months

FA-11545199 | November 2025